PCM
BDSX icon

Prelude Capital Management’s Biodesix BDSX Stock Holding History

Prelude Capital Management’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-585
Closed -$7.32K – 1020
2025
Q1 		$7.32K Buy
+585
New +$11.2K ﹤0.01% 1139
2021
Q1 		– Sell
-1,436
Closed -$579K – 1533
2020
Q4 		$579K Buy
+1,436
New +$447K 0.01% 673

Other funds holding BDSX

TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Prelude Capital Management's BDSX Position: Q2 2025 in Review

Prelude Capital Management sold out of Biodesix (BDSX) in Q2 2025, closing a stake of 585 shares — an estimated $7.32K sold.

Prelude Capital Management first reported a position in BDSX in Q4 2020 and held it in 2 quarters. The position peaked at $579K in Q4 2020. 40 funds tracked by Wall St. Rank hold BDSX as of Q2 2025.

  • Prelude Capital Management reported no remaining Biodesix position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 585 Biodesix shares in Q2 2025, an estimated $7.32K.
  • Prelude Capital Management first reported a position in Biodesix in Q4 2020 and held it in 2 quarters.
  • Prelude Capital Management's Biodesix position peaked at $579K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held Biodesix as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.